1.Persistent hypoglycemic hemiplegia: A case report.
Yong S LEE ; Byung K KIM ; Ja S KOO ; Chang H YUN ; Sung H KIM ; Han B LEE ; Seong H PARK
Journal of the Korean Neurological Association 1997;15(1):237-240
Hypoglycemia sometimes manifests as focal neurologic deficits simulating cerebrovascular disease. Symptoms are usually resolved by glucose infusion, but persistent hemiplegia is rarely reported. A 68-year-old diabetic woman on oral hypoglycemic agent(OHA) was admitted with right hemiplegia and global aphasia. Blood glucose level was 29 mg/dl on admission. No evidence of cerebral infarct or underlying brain disease could be found on initial brain CT and follow up MRI. Focal stenosis or occlusion was also absent on MR angiography. Hemiplegia and aphasia were not improved despite adequate therapy. Hypoglycemic hemiplegia should be suspected in all diabetic patients using insulin or OHA with stroke-like episode, and we suggest that prolonged hypoglycemia may be related to persistence of neurologic deficits.
Aged
;
Angiography
;
Aphasia
;
Blood Glucose
;
Brain
;
Brain Diseases
;
Constriction, Pathologic
;
Female
;
Follow-Up Studies
;
Glucose
;
Hemiplegia*
;
Humans
;
Hypoglycemia
;
Insulin
;
Magnetic Resonance Imaging
;
Neurologic Manifestations
2.A chanting picture of eclampsia - Pusan, 1967-1989.
Eun Ju KIM ; Su Mee LEE ; Kyung Hee RHO ; Jun Hee YUN ; Barbara H MARTIN
Korean Journal of Obstetrics and Gynecology 1993;36(7):1561-1570
No abstract available.
Busan*
;
Eclampsia*
;
Female
;
Pregnancy
;
Singing*
3.A Survey on the Environmental Conditions of the CO Patients treated by Hyperbaric Oxygen Therapy.
In Dal KIM ; Dork Ro YUN ; Y O CHOI ; I C YUN ; C K LEE ; Y H YANG
Korean Journal of Preventive Medicine 1972;5(1):9-15
Carbon monoxide poisoning is one of the most serios health problems in Korea, because we have been encountered with the highest incidence of CO poisoning in the world due to the unique heating system in home called "ondal". We opened Hyperbaric chamber unit in the Seoul National University Hospital last Jan, 1969. We have treated 848 patients as of Sept. 30., 1972, around 44 months period. We collected the informations on the environmental conditions of the place where CO intoxication actually occurred by filling up the questionaire from 505 patients. The following finding were obtained. 1. Age distribution showed that the highest incidence was found in the younger age group between age of 10 to age of 29 in both sex. 2. Sex ratio of the patients was 1:1.14. 3. The socio-economic level of the patient was relatively low. 4. Housewife & housemaid were the major victims of the intoxication in the female patients & in the case of the male patient, occupational backgrounds were diverse. 5. Many patients form the middle class experienced the intoxication bu sleeping at newly built room. 6. Many intoxication has been occurred in the structure of houses where communicating doors are existing between living room & kitchen. 7. All findings obtained taught us again that CO poisoning is the serious by-product of the national fuel policy which put emphasis on the use of coal & socio-economic status is very important parameter in this hazards.
Age Distribution
;
Carbon Monoxide Poisoning
;
Coal
;
Female
;
Heating
;
Hot Temperature
;
Humans
;
Hyperbaric Oxygenation*
;
Incidence
;
Korea
;
Male
;
Poisoning
;
Seoul
;
Sex Ratio
4.A Survey on the Environmental Conditions of the CO Patients treated by Hyperbaric Oxygen Therapy.
In Dal KIM ; Dork Ro YUN ; Y O CHOI ; I C YUN ; C K LEE ; Y H YANG
Korean Journal of Preventive Medicine 1972;5(1):9-15
Carbon monoxide poisoning is one of the most serios health problems in Korea, because we have been encountered with the highest incidence of CO poisoning in the world due to the unique heating system in home called "ondal". We opened Hyperbaric chamber unit in the Seoul National University Hospital last Jan, 1969. We have treated 848 patients as of Sept. 30., 1972, around 44 months period. We collected the informations on the environmental conditions of the place where CO intoxication actually occurred by filling up the questionaire from 505 patients. The following finding were obtained. 1. Age distribution showed that the highest incidence was found in the younger age group between age of 10 to age of 29 in both sex. 2. Sex ratio of the patients was 1:1.14. 3. The socio-economic level of the patient was relatively low. 4. Housewife & housemaid were the major victims of the intoxication in the female patients & in the case of the male patient, occupational backgrounds were diverse. 5. Many patients form the middle class experienced the intoxication bu sleeping at newly built room. 6. Many intoxication has been occurred in the structure of houses where communicating doors are existing between living room & kitchen. 7. All findings obtained taught us again that CO poisoning is the serious by-product of the national fuel policy which put emphasis on the use of coal & socio-economic status is very important parameter in this hazards.
Age Distribution
;
Carbon Monoxide Poisoning
;
Coal
;
Female
;
Heating
;
Hot Temperature
;
Humans
;
Hyperbaric Oxygenation*
;
Incidence
;
Korea
;
Male
;
Poisoning
;
Seoul
;
Sex Ratio
5.Coefficient Variations of Serum Levels of Phenytoin, Carbamazepine, and Valproic Acid in Compliant Epileptics.
Hae Jung YUN ; O Y KWON ; K J PARK ; N G KIM ; T Y KIM ; S C JEON ; J G HONG ; J H KWAK ; Y H LEE ; N C CHOI ; B H LIM
Journal of the Korean Neurological Association 1999;17(1):72-78
Compliance of epileptic patients is one of the most important factors for adequate therapy. Recently, it had been shown that the variability of three serial measurement of the serum levels of antiepileptic drug(AED) may be used as an indication of the degree of compliance. Coefficient variation(CV) of serum drug levels calculated by only one AED had been used to determine the compliance in epileptic patients who took multiple AEDs. We attempted to evaluate the CV of AEDs and then find the objective clue of compliance and the compatible therapeutic planing according to CV. Ninety seven epileptic patients of outpatients department of the Gyengsang National University Hospital were entered to this study. All patients were taking medication at least for 6 months without any changes of drug regimen. Patient's information was acquired by reviewing the chart and interview with questionnaire. With these informations, we determined the compliance of the patients. Antiepileptic serum levels were measured three times at intervals of at least two to four weeks apart, and their CV was calculated. We compared the CV between the compliant and non-compliant group in each AED(phenytoin, carbamazepine , valproic acid) and three drugs in the compliant group. The mean CVs of phenytoin, carbamazepine and valproic acid in the compliant group were 18.3+/-13.0, 15.2+/-10.2 and 23.8+/-8.9, respectively(mean+/-SD). The mean of CV in the compliant and the non-compliant group were 17.9+/-10.9 and 38.8+/-27.2, respectively. The CVs of the compliant group were significantly lower than those of the non-compliant group(p<0.05). However, CVs had no significant difference between three antiepileptic drugs. This study showed that CVs of AEDs were not different between each AEDs, even though they possess different pharmacokinetic properties. Therefore, the CV of one AED can be used in determining the compliance of the epileptics who are taking multiple AEDs.
Anticonvulsants
;
Carbamazepine*
;
Compliance
;
Humans
;
Outpatients
;
Phenytoin*
;
Surveys and Questionnaires
;
Valproic Acid*
6.PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Rowan E MILLER ; Karim H EL-SHAKANKERY ; Jung-Yun LEE
Journal of Gynecologic Oncology 2022;33(3):e44-
The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with an increasing population of patients who develop acquired PARPi resistance. Coupled with those patients with primary PARPi resistance, there is an urgent need to better understand mechanisms of resistance and identify means to overcome this resistance. Combination therapy offers the potential to overcome innate and acquired resistance, by either working synergistically with PARPi or by restoring homologous recombination deficiency, targeting the homologous recombination repair pathway through an alternate strategy. We discuss mechanisms of PARPi resistance and data on novel combinations which may restore PARPi sensitivity.
7.Comparative analysis of anti-Helicobacter pylori activities of FEMY-R7 composed of Laminaria japonica and Oenothera biennis extracts in mice and humans.
Tae Su KIM ; Kyungha SHIN ; Joseph H JEON ; Ehn Kyoung CHOI ; Youngjin CHOI ; Sung Pyo LEE ; Yoon Bok LEE ; Yun Bae KIM
Laboratory Animal Research 2015;31(1):7-12
Helicobacter pylori-eliminating effects of FEMY-R7, composed of Laminaria japonica and Oenothera biennis extracts, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with total 20, 64 or 200 mg/kg/day FEMY-R7 for 2 weeks. In Campylobcter-like organism (CLO)-detection tests on gastric mucosa and feces, FEMY-R7 reduced the urease-positive reactivity in a dose-dependent manner; i.e., the positivity ratios were decreased to 70, 20, and 10% for gastric mocosa and to 80, 50, and 20% for feces. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with capsules containing total 100, 320 or 1,000 mg/man/day FEMY-R7 (matching doses for 20, 64 or 200 mg/kg/day, respectively, in mice from a body surface area-based dose translation) for 8 weeks. FEMY-R7 decreased the positivity ratios in feces to 70, 40, and 30%, respectively. In bacterial culture, H. pylori was identified from the CLO-positive stools of mice and humans. The bacterial identification ratios exhibited a good correlation between the matching doses in mice and humans. It is suggested that FEMY-R7 could be a promising functional food without tolerance as an adjunct to reduce the dosage of antibiotics for the treatment of recurrent H. pylori infection.
Animals
;
Anti-Bacterial Agents
;
Bacteria
;
Capsules
;
Feces
;
Functional Food
;
Gastric Mucosa
;
Helicobacter
;
Helicobacter pylori
;
Humans
;
Laminaria*
;
Male
;
Mice*
;
Oenothera biennis*
8.Postulated release profile of recombinant human bone morphogenetic protein-2 (rhBMP-2) from demineralized dentin matrix
In Woong UM ; Jeong Kui KU ; Bu Kyu LEE ; Pil Young YUN ; Jeong Keun LEE ; Jeong Hun NAM
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2019;45(3):123-128
Demineralized dentin matrix (DDM) has been used as a recombinant human bone morphogenetic protein-2 (rhBMP-2) carrier in many clinical trials. To optimize the clinical safety and efficacy of rhBMP-2 with DDM, efforts have been made to improve the delivery of rhBMP-2 by 1) lowering the administered dose, 2) localizing the protein, and 3) prolonging its retention time at the action site as well as the bone forming capacity of the carrier itself. The release profile of rhBMP-2 that is associated with endogenous BMP in dentin has been postulated according to the type of incorporation, which is attributed to the loosened interfibrillar space and nanoporous dentinal tubule pores. Physically adsorbed and modified, physically entrapped rhBMP-2 is sequentially released from the DDM surface during the early stage of implantation. As DDM degradation progresses, the loosened interfibrillar space and enlarged dentinal tubules release the entrapped rhBMP-2. Finally, the endogenous BMP in dentin is released with osteoclastic dentin resorption. According to the postulated release profile, DDM can therefore be used in a controlled manner as a sequential delivery scaffold for rhBMP-2, thus sustaining the rhBMP-2 concentration for a prolonged period due to localization. In addition, we attempted to determine how to lower the rhBMP-2 concentration to 0.2 mg/mL, which is lower than the approved 1.5 mg/mL.
Bone Morphogenetic Proteins
;
Collagen
;
Dentin
;
Humans
;
Osteoclasts
9.Postulated release profile of recombinant human bone morphogenetic protein-2 (rhBMP-2) from demineralized dentin matrix
In Woong UM ; Jeong Kui KU ; Bu Kyu LEE ; Pil Young YUN ; Jeong Keun LEE ; Jeong Hun NAM
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2019;45(3):123-128
Demineralized dentin matrix (DDM) has been used as a recombinant human bone morphogenetic protein-2 (rhBMP-2) carrier in many clinical trials. To optimize the clinical safety and efficacy of rhBMP-2 with DDM, efforts have been made to improve the delivery of rhBMP-2 by 1) lowering the administered dose, 2) localizing the protein, and 3) prolonging its retention time at the action site as well as the bone forming capacity of the carrier itself. The release profile of rhBMP-2 that is associated with endogenous BMP in dentin has been postulated according to the type of incorporation, which is attributed to the loosened interfibrillar space and nanoporous dentinal tubule pores. Physically adsorbed and modified, physically entrapped rhBMP-2 is sequentially released from the DDM surface during the early stage of implantation. As DDM degradation progresses, the loosened interfibrillar space and enlarged dentinal tubules release the entrapped rhBMP-2. Finally, the endogenous BMP in dentin is released with osteoclastic dentin resorption. According to the postulated release profile, DDM can therefore be used in a controlled manner as a sequential delivery scaffold for rhBMP-2, thus sustaining the rhBMP-2 concentration for a prolonged period due to localization. In addition, we attempted to determine how to lower the rhBMP-2 concentration to 0.2 mg/mL, which is lower than the approved 1.5 mg/mL.
10.Anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract in mice and humans.
Tae Su KIM ; Ehn Kyoung CHOI ; Jihyun KIM ; Kyungha SHIN ; Sung Pyo LEE ; Youngjin CHOI ; Joseph H JEON ; Yun Bae KIM
Laboratory Animal Research 2014;30(3):131-135
Helicobacter pylori-eliminating effects of FEMY-R7, composed of fucoidan and evening primrose extract, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10 or 100 mg/kg FEMY-R7 for 2 weeks. In Campylobcter-like organism-detection test, FEMY-R7 markedly reduced the urease-positive reactivity. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with a capsule containing 150 mg FEMY-R7 for 8 weeks. FEMY-R7 significantly decreased both the Delta over baseline-value in urea breath test and the serum pepsinogens I and II levels. The results indicate that FEMY-R7 not only eliminates H. pylori from gastric mucosa of animals and humans, but also improves gastric function.
Animals
;
Bacteria
;
Breath Tests
;
Gastric Mucosa
;
Helicobacter
;
Helicobacter pylori
;
Humans
;
Male
;
Mice*
;
Oenothera biennis*
;
Pepsinogen A
;
Pepsinogens
;
Urea